API | quisinostat

quisinostat Report issue

Small molecule Experimental

AACT ChEMBL DrugBank MeSH PubChem

Active Ingredient History

NOW

Quisinostat is an experimental drug candidate for the treatment of cancer. It is a "second generation" histone deacetylase inhibitor with antineoplastic activity. It is highly potent against class I and II HDACs. ^Wikipedia

Chemistry

SMILES: Cn1cc(CNCC2CCN(CC2)c3ncc(cn3)C(=O)NO)c4ccccc14
InChIKey: PAWIYAYFNXQGAP-UHFFFAOYSA-N
Mol. Mass: 394.48
ALogP: 2.09 Partition coefficient
ChEMBL Molecule:
quisinostat

More Chemistry

Pharmacology

Mechanism of Action:
- Histone deacetylase 2 (Homo sapiens) ^UniProt
Multi-specific: Missing data
Black Box: No
Availability: Missing data
Delivery Methods: Missing data
Pro Drug: No

jnj-2641585 | jnj26481585 | jnj 26481585 | jnj-26481585 | quisinostat

Organizations (4)

Research & Development (4)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (0)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (9)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (9)

Carcinoma, Non-Small-Cell Lung (Phase 1)

Carcinoma, Ovarian Epithelial (Phase 1)

Leukemia (Phase 1)

Lymphoma (Phase 1)

Lymphoma, T-Cell, Cutaneous (Phase 2)

Multiple Myeloma (Phase 1)

Myelodysplastic Syndromes (Phase 1)

Neoplasms (Phase 1)

Ovarian Neoplasms (Phase 2)

Overview

Highest Phase: Phase 2
# of Trials: 6
# of Trial Organizations: 4

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue